Top

Published in:

01-05-2012 | Original Research Article

The Impact of Co-Morbidity Burden on Preference-Based Health-Related Quality of Life in the United States

Authors: Dr Patrick W. Sullivan, PhD, Vahram H. Ghushchyan, Elizabeth A. Bayliss

Published in: PharmacoEconomics | Issue 5/2012

Abstract

Background: Many statistical analyses, clinical trials and cost-utility analyses designed to measure the impact of a particular disease on utility scores often overlook the important influence of co-morbidity burden.

Objectives: This study aims to examine the impact of co-morbidity burden on EQ-5D index scores in a nationally representative sample of the US.

Methods: The pooled 2001 and 2003 Medical Expenditure Panel Survey was used. The total number of chronic conditions for each individual was calculated based on Clinical Classification Categories codes. Spline regression was used to identify nonlinear age effects: individuals were separated into four quartiles based on age. Censored least absolute deviation was used to regress EQ-5D index scores on age and chronic co-morbidity, controlling for income, gender, race, ethnicity, education, physical activity and smoking status. Interactions between age and chronic conditions were also explored.

Results: The coefficients for chronic co-morbidities were highly statistically significant with large magnitudes for those with two or more chronic conditions (coefficient two chronic conditions=-0.16; coefficient nine chronic conditions=-0.28). After controlling for chronic co-morbidities and other confounders, age was not statistically significant except for those aged >58 years and the magnitude of this coefficient was very small (coefficient aged >58 years=-0.0006). The interactions between age and chronic comorbidity were significant, but the deleterious impact of their interaction was largely dominated by the existence and number of chronic conditions.

Conclusions: Chronic conditions have a significant deleterious impact on EQ-5D index scores that is much more pronounced than age and other sociodemographic and behavioural characteristics. Future analyses and costutility models should incorporate the impact of multiple morbidity.

Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996

Drummond MF. Methods for the economic evaluation of health care programmes. 2nd rev. ed. Oxford: Oxford University Press, 1997

van den Akker M, Buntinx F, Roos S, et al. Problems in determining occurrence rates of multimorbidity. J Clin Epidemiol 2001; 54: 675–9PubMedCrossRef

Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162: 2269–76PubMedCrossRef

Fortin M, Bravo G, Hudon C, et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005; 3: 223–8PubMedCrossRef

Kahn LS, Fox CH, Olawaiye A, et al. Facilitating quality improvement in physician management of comorbid chronic disease in an urban minority practice. J Natl Med Assoc 2007; 99: 377–83PubMed

Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care. Qual Life Res 2006; 15: 83–91PubMedCrossRef

Gijsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001; 54: 661–74PubMedCrossRef

Bayliss EA, Bayliss MS, Ware Jr JE, et al. Predicting declines in physical function in persons with multiple chronic medical conditions: what we can learn from the medical problem list. Health Qual Life Outcomes 2004; 2: 47PubMedCrossRef

10.

Noel PH, Williams Jr JW, Unutzer J, et al. Depression and comorbid illness in elderly primary care patients: impact on multiple domains of health status and well-being. Ann Fam Med 2004; 2: 555–62PubMedCrossRef

11.

Center for Financing, Access, and Cost Trends. Medical Expenditure Panel Survey: HC-097 2005 full year consolidated data file. Rockville (MD): AHRQ, 2007 [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h97/h97doc.shtml [Accessed 2012 Jan 19]

12.

Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey [online]. Available from URL: http://www.meps.ahrq.gov [Accessed 2012 Jan 19]

13.

Elixhauser A. Clinical classifications for health policy research, version 2: software and user’s guide [publication no.96-0046]. Rockville (MD): AHRQ, 1996

14.

Agency for Healthcare Research and Quality. MEPS HC-078: 2003 medical conditions file. Rockville (MD): AHRQ, 2003 [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data_stats/download_data_files_detail.jsp?cboPufNumber=HC-078 [Accessed 2008 Jul 23]

15.

Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006; 26: 410–20PubMedCrossRef

16.

Sullivan PW, Lawrence Jr WF, Ghushchyan V. A national catalogue of preference-based scores for chronic conditions in the U.S. Med Care 2005; 43: 736–49PubMedCrossRef

17.

Hwang W, Weller W, Ireys H, et al. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood) 2001; 20: 267–78CrossRef

18.

EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208CrossRef

19.

McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 2nd rev. ed. New York: Oxford University Press, 1996

20.

EuroQol Group. EQ-5D: a standardised instrument for use as a measure of health outcome [online]. Available from URL: http://www.euroqol.org [Accessed 2008 Jul 23]

21.

Shaw JW, Johnson JA, Coons SJ. U.S. valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43 (3): 203–20PubMedCrossRef

22.

Stata [computer program]. Version 9.2. College Station (TX): StataCorp, 2006

23.

Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making 2006; 26: 401–9PubMedCrossRef

24.

Lubetkin EI, Jia H, Franks P, et al. Relationship among sociodemographic factors, clinical conditions, and healthrelated quality of life: examining the EQ-5D in the U.S. general population. Qual Life Res 2005; 14: 2187–96PubMedCrossRef

25.

Ko Y, Coons SJ. Self-reported chronic conditions and EQ-5D index scores in the US adult population. Curr Med Res Opin 2006; 22: 2065–71PubMedCrossRef

26.

Fu AZ, Kattan MW. Racial and ethnic differences in preference-based health status measure. Curr Med Res Opin 2006; 22: 2439–48PubMedCrossRef

27.

Basu A, Dale W, Elstein A, et al. A linear index for predicting joint health-states utilities from single health-states utilities. Health Econ 2009; 18: 403–19PubMedCrossRef

28.

Hanmer J, Vanness D, Gangnon R, et al. Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditions. J Clin Epidemiol 2010; 63 (3): 331–41PubMedCrossRef

29.

Bo H, Fu AZ. Predicting utility for joint health states: a general framework and a new nonparametric estimator. Med Decis Making 2010; 30 (5): E29–39CrossRef

30.

Schneeweiss S, Wang PS, Avorn J, et al. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med 2004; 19: 444–50PubMedCrossRef

31.

Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854–64PubMedCrossRef

32.

Byles JE, D’Este C, Parkinson L, et al. Single index of multimorbidity did not predict multiple outcomes. J Clin Epidemiol 2005; 58: 997–1005PubMedCrossRef

33.

Crabtree HL, Gray CS, Hildreth AJ, et al. The comorbidity symptomscale: a combined disease inventory and assessment of symptom severity. J Am Geriatr Soc 2000; 48: 1674–8PubMed

34.

Fan VS, Au D, Heagerty P, et al. Validation of case-mix measures derived from self-reports of diagnoses and health. J Clin Epidemiol 2002; 55: 371–80PubMedCrossRef

35.

Hallstrom AP, Cobb LA, Yu BH. Influence of comorbidity on the outcome of patients treated for out-of-hospital ventricular fibrillation. Circulation 1996; 93: 2019–22PubMedCrossRef

36.

Robinson JR, Young TK, Roos LL, et al. Estimating the burden of disease: comparing administrative data and self-reports. Med Care 1997; 35: 932–47PubMedCrossRef

37.

Silliman RA, Lash TL. Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients. Med Care 1999; 37: 339–49PubMedCrossRef

38.

Berkanovic E, Telesky C. Mexican-American, black-American and white-American differences in reporting illnesses, disability and physician visits for illnesses. Soc Sci Med 1985; 20: 567–77PubMedCrossRef

39.

Stewart AL, Napoles-Springer A. Health-related quality-oflife assessments in diverse population groups in the United States. Med Care 2000; 38 (9 Suppl.): II 102–24

40.

Johnson TP, O’Rourke D, Chavez N, et al. Cultural variations in the interpretation of health survey questions. In: Warnecke RB, editor. Health survey research methods. Hyattsville (MD): National Center for Health Statistics, 1996: 57–62

Title: The Impact of Co-Morbidity Burden on Preference-Based Health-Related Quality of Life in the United States
Authors: Dr Patrick W. Sullivan, PhD
Vahram H. Ghushchyan
Elizabeth A. Bayliss
Publication date: 01-05-2012
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 5/2012
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/11586840-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Impact of Co-Morbidity Burden on Preference-Based Health-Related Quality of Life in the United States

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Issues in the Economic Evaluation of Influenza Vaccination by Injection of Healthy Working Adults in the US

Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals

Human Papillomavirus Vaccination Is Not Exclusively a Matter of Price

Pharmacoeconomics of Bisphosphonates for Skeletal-Related Event Prevention in Metastatic Non-Breast Solid Tumours

The Authors’ Reply

Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US